Chen group used BMS-1198 (a small-molecule PD-L1 inhibitor) and pomalidomide (a CRBN ligand) to synthesize PROTAC P22, which moderately degraded PD-L1 in lung and breast cancer cells [215]. The gene discussed is CD274; the disease is breast cancer.